ArticleJournal of psychopharmacology (Oxford, England)2022
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
Article in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.Journal of psychopharmacology (Oxford, England) · 2026Article
- Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry.The lancet. Psychiatry · 2026Review
- Article
- The science of psychedelic medicine.Nature medicine · 2026Review
- Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico.Frontiers in public health · 2026Article
- Health-related behavioral changes following the use of psychedelics in naturalistic settings.Preventive medicine reports · 2025Article
- An international Delphi consensus for reporting of setting in psychedelic clinical trials.Nature medicine · 2025Article
- Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.Drug safety · 2025Article
- Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.Therapeutic advances in psychopharmacology · 2025Review
- Psychiatric risks for worsened mental health after psychedelic use.Journal of psychopharmacology (Oxford, England) · 2024Review
- Development of a digital intervention for psychedelic preparation (DIPP).Scientific reports · 2024Article
- Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial.BMC psychiatry · 2024Article
- The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.Scientific reports · 2023Article
- Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.Journal of psychopharmacology (Oxford, England) · 2023Article
- Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.Frontiers in psychiatry · 2023Review
- Psychedelic therapy in the treatment of addiction: the past, present and future.Frontiers in psychiatry · 2023Review
- Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings.Frontiers in human neuroscience · 2023Article
- Expectancy in placebo-controlled trials of psychedelics: if so, so what?Psychopharmacology · 2022Article
- Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.Journal of psychopharmacology (Oxford, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Favourable regulatory assessments, liberal policy changes, new research centres and substantial commercial investment signal that psychedelic therapy is making a major comeback. Positive findings from modern trials are catalysing developments, but it is questionable whether current confirmatory trials are sufficient for advancing our understanding of safety and best practice. Here we suggest supplementing traditional confirmatory trials with pragmatic trials, real-world data initiatives and digital health solutions to better support the discovery of optimal and personalised treatment protocols and parameters. These recommendations are intended to help support the development of safe, effective and cost-efficient psychedelic therapy, which, given its history, is vulnerable to excesses of hype and regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.